Targeted therapy strategy for the treatment of breast cancer in the spanning trastuzumab era        WANG Tao,JIANG Ze-fei. Affiliated Hospital, Academy of Military Medical Science(the 307 Hospital of PLA), Beijing100071,China
Corresponding author: JIANG Ze-fei, E-mail: jiangzefei@medmail.com.cn
Abstract    Breast cancer is a complex and heterogeneous disease. Targeted therapies for breast cancer are evolving rapidly. Trastuzumab therapy for HER?2-positive metastatic breast cancer was approved by FDA in 1997. Since that day, other targeted therapies, such as lapatinib, a dual human epidermal growth factor receptor HER1 and HER?2 inhibitor, bevacizumab, a monoclonal antibody targeting angiogenesis, have been used in clinical practice. Other targeted drugs which have been approved in other cancer, such as gefitinib, sorafenib, have shown good activity in breast cancer. Additionally many new drugs like T-DM1 are being assessed in breast cancer.